Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone. Ozempic for blood sugar control and Wegovy for weight loss both use different ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

Although Ana was adamant she wanted to use the jabs – which can be prescribed on the NHS if you’re over 30 BMI or 27 BMI with ...

With up to 800 obese patients in Kent now eligible for Mounjaro on the NHS, those already using the weight loss jabs share their incredible stories.

Around a fifth of users report not losing the expected amounts of weight on Mounjaro, and doctors have some answers ...

Insulin changed the way we treat and manage diabetes. Chemotherapy has precipitously reduced the mortality rate of certain ...

The quest for weight loss has taken a dramatic turn. A wave of new-age solutions, from once-weekly injectables like Wegovy ...

As a mass rollout of weight loss injections begins across the NHS, with GPs able to prescribe Mounjaro for the first time ...

Weight-loss drugs suppress appetite and can cut 'food noise' - but deplete energy and worsen fatigue. Here's how Maria Shahid ...

Mounjaro has been approved for both type 2 diabetes and weight loss, but access will be limited by strict eligibility ...